Frontotemporal dementia is a rare form of Alzheimer disease that changes personality and behavior before memory fades. Doctors need better ways to tell these conditions apart early on. A recent study looked at retinal scans to see if they could help. The researchers examined eye layers in 139 people with frontotemporal dementia and compared them to others with Alzheimer disease or mild cognitive impairment. They also included healthy controls in the comparison group. The total group had 29 people with mild cognitive impairment and 14 with TDP-43 proteinopathy. Five people had tauopathy. The team measured retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness using optical coherence tomography. This technology uses light to take detailed pictures of the eye. The results showed that the retinal nerve fiber layer was significantly thinner in individuals with frontotemporal dementia compared with Alzheimer disease. The ganglion cell layer-inner plexiform layer was also significantly thinner in those with frontotemporal dementia compared with controls. When the team pooled data across multiple retinal biomarkers, the differences were not significant. The study did not report any safety issues because no medications were tested. The authors noted that larger longitudinal studies with standardized protocols are needed to determine the diagnostic and prognostic utility of retinal biomarkers in frontotemporal dementia.
Systematic review and meta-analysis of retinal biomarkers in frontotemporal dementia and Alzheimer diseaseRetinal scans show thinner layers in frontotemporal dementia than Alzheimer disease
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This is a systematic review and meta-analysis of retinal biomarkers measured by optical coherence tomography (OCT) and OCT angiography in individuals with frontotemporal dementia (FTD), Alzheimer disease (AD), mild cognitive impairment, TDP-43 proteinopathy, tauopathy, and controls. The analysis included 139 individuals with FTD, 87 with AD, 29 with mild cognitive impairment, 14 with TDP-43 proteinopathy, 5 with tauopathy, and 255 controls.
The authors synthesized findings on retinal nerve fiber layer (RNFL) thickness and ganglion cell layer-inner plexiform layer (GCL-IPL) thickness. For RNFL thickness, the meta-analysis found it was significantly thinner in individuals with FTD compared with AD, with a standardized mean difference (SMD) of -0.61 (95% CI -0.98, -0.24). For GCL-IPL thickness, it was significantly thinner in individuals with FTD compared with controls, with an SMD of -0.55 (95% CI -1.02, -0.08). Pooled analyses across multiple retinal biomarkers were non-significant (SMD -0.19, 95% CI -0.52, 0.14).
The authors acknowledge key limitations, including the need for larger longitudinal studies with standardized OCT/OCTA protocols to determine the diagnostic and prognostic utility of retinal biomarkers in FTD. Follow-up duration and safety data were not reported.
Practice relevance was not reported, and the findings should be interpreted as preliminary evidence from a meta-analysis, not as a basis for clinical decision-making.